Merck & Co., Inc. (NYSE:MRK) Updates FY20 Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) updated its FY20 earnings guidance on Friday. The company provided earnings per share guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.Merck & Co., Inc. also updated its FY 2020
Pre-Market guidance to 5.63-5.78 EPS.

Several research firms recently issued reports on MRK. Morgan Stanley reaffirmed a buy rating and issued a $89.00 price target on shares of Merck & Co., Inc. in a report on Tuesday, June 23rd. Guggenheim cut their price target on shares of Merck & Co., Inc. from $101.00 to $93.00 and set a buy rating on the stock in a report on Wednesday, April 29th. UBS Group cut their price target on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a buy rating on the stock in a report on Monday, April 13th. Wolfe Research cut shares of Merck & Co., Inc. from an outperform rating to a peer perform rating in a report on Friday, June 12th. Finally, Credit Suisse Group reaffirmed a buy rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a report on Monday, May 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. Merck & Co., Inc. currently has an average rating of Buy and an average price target of $94.15.

Shares of NYSE:MRK traded up $1.25 on Friday, reaching $80.24. 11,726,443 shares of the company’s stock were exchanged, compared to its average volume of 7,395,451. The firm has a market capitalization of $202.53 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 2.20 and a beta of 0.48. Merck & Co., Inc. has a fifty-two week low of $65.25 and a fifty-two week high of $92.64. The business’s 50-day moving average is $77.65 and its two-hundred day moving average is $79.99. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 31st. The company reported $1.37 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.23. The company had revenue of $10.87 billion for the quarter, compared to analysts’ expectations of $10.52 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. During the same period in the prior year, the company earned $1.30 earnings per share. The firm’s revenue was down 7.6% compared to the same quarter last year. Analysts predict that Merck & Co., Inc. will post 5.32 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.61 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.04%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 47.01%.

In related news, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the sale, the director now owns 5,100 shares of the company’s stock, valued at approximately $387,702. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Julie L. Gerberding sold 36,285 shares of the stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $80.00, for a total transaction of $2,902,800.00. Following the completion of the sale, the executive vice president now directly owns 62,862 shares in the company, valued at approximately $5,028,960. The disclosure for this sale can be found here. 0.28% of the stock is owned by company insiders.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Rule of 72

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.